CN1526718A - 抗病毒和抗肿瘤的含CpG单链脱氧寡核苷酸 - Google Patents
抗病毒和抗肿瘤的含CpG单链脱氧寡核苷酸 Download PDFInfo
- Publication number
- CN1526718A CN1526718A CNA031198406A CN03119840A CN1526718A CN 1526718 A CN1526718 A CN 1526718A CN A031198406 A CNA031198406 A CN A031198406A CN 03119840 A CN03119840 A CN 03119840A CN 1526718 A CN1526718 A CN 1526718A
- Authority
- CN
- China
- Prior art keywords
- dna
- artificial
- cpg
- cell
- single chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000259 anti-tumor effect Effects 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims abstract description 42
- 239000003814 drug Substances 0.000 claims abstract description 14
- 102000006992 Interferon-alpha Human genes 0.000 claims abstract description 11
- 108010047761 Interferon-alpha Proteins 0.000 claims abstract description 11
- 208000032839 leukemia Diseases 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 22
- 230000009385 viral infection Effects 0.000 claims description 12
- 230000001613 neoplastic effect Effects 0.000 claims description 11
- 208000036142 Viral infection Diseases 0.000 claims description 10
- 108091034117 Oligonucleotide Proteins 0.000 claims description 7
- 206010052428 Wound Diseases 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 210000005087 mononuclear cell Anatomy 0.000 claims description 4
- 238000004073 vulcanization Methods 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 abstract description 120
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract description 10
- 102000053602 DNA Human genes 0.000 abstract description 3
- 208000035473 Communicable disease Diseases 0.000 abstract description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 2
- 230000003612 virological effect Effects 0.000 abstract 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 54
- 244000309466 calf Species 0.000 description 34
- 210000002966 serum Anatomy 0.000 description 34
- 239000007788 liquid Substances 0.000 description 33
- 239000012980 RPMI-1640 medium Substances 0.000 description 30
- 238000000034 method Methods 0.000 description 26
- 239000000243 solution Substances 0.000 description 26
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- 102000014150 Interferons Human genes 0.000 description 15
- 108010050904 Interferons Proteins 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 15
- 229940079322 interferon Drugs 0.000 description 14
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 12
- 235000011089 carbon dioxide Nutrition 0.000 description 12
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 12
- 230000009849 deactivation Effects 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 10
- 239000011886 peripheral blood Substances 0.000 description 10
- 210000005259 peripheral blood Anatomy 0.000 description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 239000005289 controlled pore glass Substances 0.000 description 9
- 235000015097 nutrients Nutrition 0.000 description 9
- -1 phosphoramidite triester Chemical class 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 210000000822 natural killer cell Anatomy 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 7
- 238000011010 flushing procedure Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 6
- 229930182566 Gentamicin Natural products 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000004821 distillation Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229960002518 gentamicin Drugs 0.000 description 6
- 238000012856 packing Methods 0.000 description 6
- 238000000967 suction filtration Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000006482 condensation reaction Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 238000009527 percussion Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000013024 dilution buffer Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000383 hazardous chemical Substances 0.000 description 3
- 230000007365 immunoregulation Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000000274 microglia Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 2
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- GCHCDBOIRFPABI-UHFFFAOYSA-N NP(O)O.C1=NN=NN1.C1=NN=NN1 Chemical compound NP(O)O.C1=NN=NN1.C1=NN=NN1 GCHCDBOIRFPABI-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000000118 anti-neoplastic effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000001045 blue dye Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010411 cooking Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 231100000652 hormesis Toxicity 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002516 radical scavenger Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 108091032917 Transfer-messenger RNA Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical group OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002399 phagocytotic effect Effects 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 238000013379 physicochemical characterization Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000005987 sulfurization reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L2924/00—Indexing scheme for arrangements or methods for connecting or disconnecting semiconductor or solid-state bodies as covered by H01L24/00
- H01L2924/10—Details of semiconductor or other solid state devices to be connected
- H01L2924/11—Device type
- H01L2924/14—Integrated circuits
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L2924/00—Indexing scheme for arrangements or methods for connecting or disconnecting semiconductor or solid-state bodies as covered by H01L24/00
- H01L2924/19—Details of hybrid assemblies other than the semiconductor or other solid state devices to be connected
- H01L2924/1901—Structure
- H01L2924/1904—Component type
- H01L2924/19043—Component type being a resistor
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
编号 | 序列 | 杀伤率(%) |
TE | 对照组 | 56.834 |
660 | 5’-ggACgATCgATCgTgggggg-3’ | 68.792 |
661 | 5’-gggATgCATCgATgCATCgggggg-3’ | 74.831 |
662 | 5’-gggggAATCgATTCgggggg-3’ | 66.534 |
663 | 5’-ggTgCgACgTCgCAgggggg-3’ | 64.597 |
664 | 5’-TCgTCgggTgCATCgATgCAgggggg-3’ | 73.803 |
665 | 5’-ggTgCATCgTACgATgCAgggggg-3’ | 69.429 |
666 | 5’-gggACgTACgTCgggggg-3’ | 71.594 |
667 | 5’-TCggggACgATCgTCgggggg-3’ | 67.024 |
668 | 5’-gggggATCgATATCgATCgggggg-3’ | 75.312 |
669 | 5’-gggggATCgACgTCgATCgggggg-3’ | 70.107 |
670 | 5’-ggTgCATCgATCgATgCAgggggg-3’ | 72.119 |
671 | 5’-ggATCgATCgATCgATgggggg-3’ | 70.107 |
672 | 5’-ggCgATCgATCgATCggggggg-3’ | 65.745 |
673 | 5’-ggggTCgATCgATCgAgggggg-3’ | 76.536 |
674 | 5’-ggTgCgATCgATCgCAgggggg-3’ | 70.741 |
675 | 5’-ggTCgCgATCgCgAgggggg-3’ | 77.805 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031198406A CN100486987C (zh) | 2003-03-05 | 2003-03-05 | 抗病毒和抗肿瘤的含CpG单链脱氧寡核苷酸 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031198406A CN100486987C (zh) | 2003-03-05 | 2003-03-05 | 抗病毒和抗肿瘤的含CpG单链脱氧寡核苷酸 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1526718A true CN1526718A (zh) | 2004-09-08 |
CN100486987C CN100486987C (zh) | 2009-05-13 |
Family
ID=34285290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031198406A Expired - Lifetime CN100486987C (zh) | 2003-03-05 | 2003-03-05 | 抗病毒和抗肿瘤的含CpG单链脱氧寡核苷酸 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100486987C (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006056142A1 (fr) | 2004-11-29 | 2006-06-01 | Changchun Huapu Biotechnology Co., Ltd. | Desoxynucleotides cpg a brin unique a utiliser comme adjuvant |
WO2006108358A1 (fr) * | 2005-04-13 | 2006-10-19 | Changchun Huapu Biotechnology Co., Ltd. | UTILISATION ANTIVIRALE D’OLIGODESOXYNUCLEOTIDES ARTIFICIELS A UN SEUL BRIN CONTENANT UN CpG EN COMBINAISON AVEC LA RIBAVIRINE |
WO2006122464A1 (en) * | 2005-05-17 | 2006-11-23 | Changchun Huapu Biotechnology Co., Ltd. | An oligonucleotide or its functional homologue, a composition comprising the same and a method for treating b cell neoplasm |
WO2007012285A1 (fr) * | 2005-07-28 | 2007-02-01 | Changchun Huapu Biotechnology Co., Ltd. | Desoxynucleosides monocatenaires resistant aux infections virales |
CN1304412C (zh) * | 2003-09-05 | 2007-03-14 | 长春华普生物技术有限公司 | 抗单股正链RNA病毒人工合成的含CpG单链脱氧寡核苷酸 |
CN101161288A (zh) * | 2006-10-13 | 2008-04-16 | 长春华普生物技术有限公司 | 寡核苷酸增强的肿瘤细胞裂解物及其用于治疗肿瘤的方法 |
CN100402090C (zh) * | 2006-06-15 | 2008-07-16 | 南京农业大学 | 一种黏膜免疫的复合佐剂 |
CN101148467B (zh) * | 2006-09-20 | 2012-03-14 | 长春华普生物技术有限公司 | 一种寡核苷酸及其治疗肺癌的用途 |
WO2017101744A1 (zh) * | 2015-12-17 | 2017-06-22 | 苏州派动生物技术有限公司 | 具有抗原增效作用和肿瘤治疗作用的寡核苷酸 |
US9969781B2 (en) | 2006-12-04 | 2018-05-15 | Tapas Das Gupta | Compositions and methods to treat cancer with CpG rich DNA and cupredoxins |
-
2003
- 2003-03-05 CN CNB031198406A patent/CN100486987C/zh not_active Expired - Lifetime
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1304412C (zh) * | 2003-09-05 | 2007-03-14 | 长春华普生物技术有限公司 | 抗单股正链RNA病毒人工合成的含CpG单链脱氧寡核苷酸 |
WO2006056142A1 (fr) | 2004-11-29 | 2006-06-01 | Changchun Huapu Biotechnology Co., Ltd. | Desoxynucleotides cpg a brin unique a utiliser comme adjuvant |
US7745598B2 (en) | 2004-11-29 | 2010-06-29 | Changchun Huapu Biotechnology Co., Ltd. | CpG single strand deoxynucleotides for use as adjuvant |
JP2008521385A (ja) * | 2004-11-29 | 2008-06-26 | 長春華普生物技術有限公司 | アジュバントとしてのCpG含有一本鎖デオキシヌクレオチド |
WO2006108358A1 (fr) * | 2005-04-13 | 2006-10-19 | Changchun Huapu Biotechnology Co., Ltd. | UTILISATION ANTIVIRALE D’OLIGODESOXYNUCLEOTIDES ARTIFICIELS A UN SEUL BRIN CONTENANT UN CpG EN COMBINAISON AVEC LA RIBAVIRINE |
CN1865275B (zh) * | 2005-05-17 | 2011-06-15 | 长春华普生物技术有限公司 | 对人b细胞肿瘤有治疗作用的人工合成的单链脱氧核苷酸 |
JP4837033B2 (ja) * | 2005-05-17 | 2011-12-14 | チャンチュン ファプ バイオテクノロジー カンパニー リミテッド | オリゴヌクレオチドまたはその機能的相同体、それらを含有する組成物およびb細胞腫瘍を治療する方法 |
EP1883647A1 (en) * | 2005-05-17 | 2008-02-06 | Changchun Huapu Biotechnology Co., Ltd. | Oligonucleotides or their functional homologues, a composition comprising the same and a method of treating b cell neoplasm |
US8450292B2 (en) | 2005-05-17 | 2013-05-28 | Changchun Huapu Biotechnology Co., Ltd. | Oligonucleotides or their functional homologues, a composition comprising the same and a method of treating B cell neoplasm |
AU2006246897B2 (en) * | 2005-05-17 | 2012-04-12 | Changchun Huapu Biotechnology Co., Ltd. | Oligonucleotides or their functional homologues, a composition comprising the same and a method of treating B cell neoplasm |
US8133874B2 (en) | 2005-05-17 | 2012-03-13 | Changchun Huapu Biotechnology Co., Ltd. | Oligonucleotide or its functional homologue, a composition comprising the same and a method of treating B cell neoplasm |
WO2006122463A1 (en) * | 2005-05-17 | 2006-11-23 | Changchun Huapu Biotechnology Co., Ltd. | Oligonucleotides or their functional homologues, a composition comprising the same and a method of treating b cell neoplasm |
EP1883647A4 (en) * | 2005-05-17 | 2010-10-06 | Changchun Huapu Biotechnology | OLIGONUCLEOTIDES OR FUNCTIONAL COMPONENTS THEREOF, COMPOSITION COMPRISING SAME, AND METHOD FOR TREATING B-CELL TUMOR |
EP1883411A4 (en) * | 2005-05-17 | 2010-10-06 | Changchun Huapu Biotechnology | OLIGONUCLEOTIDE OR ITS FUNCTIONAL APPROVAL, COMPOSITION COMPRISING SAME, AND PROCESS FOR TREATING A B CELL TUMOR |
WO2006122464A1 (en) * | 2005-05-17 | 2006-11-23 | Changchun Huapu Biotechnology Co., Ltd. | An oligonucleotide or its functional homologue, a composition comprising the same and a method for treating b cell neoplasm |
AU2006246898B2 (en) * | 2005-05-17 | 2011-08-18 | Changchun Huapu Biotechnology Co., Ltd. | An oligonucleotide or its functional homologue, a composition comprising the same and a method for treating B cell neoplasm |
EP1883411A1 (en) * | 2005-05-17 | 2008-02-06 | Changchun Huapu Biotechnology Co., Ltd. | An oligonucleotide or its functional homologue, a composition comprising the same and a method for treating b cell neoplasm |
JP4837034B2 (ja) * | 2005-05-17 | 2011-12-14 | チャンチュン ファプ バイオテクノロジー カンパニー リミテッド | オリゴヌクレオチドまたはその機能的相同体、それらを含有する組成物およびb細胞腫瘍を治療するための方法 |
WO2007012285A1 (fr) * | 2005-07-28 | 2007-02-01 | Changchun Huapu Biotechnology Co., Ltd. | Desoxynucleosides monocatenaires resistant aux infections virales |
CN100402090C (zh) * | 2006-06-15 | 2008-07-16 | 南京农业大学 | 一种黏膜免疫的复合佐剂 |
CN101148467B (zh) * | 2006-09-20 | 2012-03-14 | 长春华普生物技术有限公司 | 一种寡核苷酸及其治疗肺癌的用途 |
CN101161288A (zh) * | 2006-10-13 | 2008-04-16 | 长春华普生物技术有限公司 | 寡核苷酸增强的肿瘤细胞裂解物及其用于治疗肿瘤的方法 |
CN101161288B (zh) * | 2006-10-13 | 2013-07-03 | 长春华普生物技术有限公司 | 寡核苷酸增强的肿瘤细胞裂解物及其在制备治疗肿瘤的药物中的应用 |
US9969781B2 (en) | 2006-12-04 | 2018-05-15 | Tapas Das Gupta | Compositions and methods to treat cancer with CpG rich DNA and cupredoxins |
US11046733B2 (en) | 2006-12-04 | 2021-06-29 | The Board Of Trustees Of The University Of Illinois | Compositions and methods to treat cancer with CpG rich DNA and cupredoxins |
WO2017101744A1 (zh) * | 2015-12-17 | 2017-06-22 | 苏州派动生物技术有限公司 | 具有抗原增效作用和肿瘤治疗作用的寡核苷酸 |
CN106893724A (zh) * | 2015-12-17 | 2017-06-27 | 苏州派动生物技术有限公司 | 具有抗原增效作用和肿瘤治疗作用的寡核苷酸 |
CN106893724B (zh) * | 2015-12-17 | 2023-05-02 | 苏州派动生物技术有限公司 | 具有抗原增效作用和肿瘤治疗作用的寡核苷酸 |
Also Published As
Publication number | Publication date |
---|---|
CN100486987C (zh) | 2009-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1810970A (zh) | 含CpG的单链脱氧核苷酸与其疫苗组合物及其应用 | |
CN1630535A (zh) | Stat-1之抑制 | |
CN1836042A (zh) | 用于基因沉默的hbv和hcv保守序列 | |
CN1526718A (zh) | 抗病毒和抗肿瘤的含CpG单链脱氧寡核苷酸 | |
CN1543501A (zh) | 抗原特异性细胞毒性t细胞的扩大培养方法 | |
CN1839202A (zh) | 细胞毒性淋巴细胞的制备方法 | |
CN1509337A (zh) | IFNα-17基因的新的多核苷酸和多肽 | |
CN1865275A (zh) | 对人b细胞肿瘤有治疗作用的人工合成的单链脱氧核苷酸 | |
CN1526719A (zh) | 增强蛋白类疫苗免疫效果的含CpG单链脱氧寡核苷酸 | |
CN1771054A (zh) | 改进的疫苗 | |
CN101067149A (zh) | Cyp3a检测芯片及其应用 | |
CN1160454C (zh) | 用于抗日本脑炎病毒感染的灭活疫苗的增强免疫原及其生产方法 | |
CN1313491C (zh) | 猫ω干扰素及其编码基因与应用 | |
CN1161468C (zh) | Mpl配体类似物 | |
CN1273021C (zh) | 含丙酯草醚或异丙酯草醚的油菜田除草剂组合物 | |
CN1566131A (zh) | 攻击人类乙型肝炎病毒的小干扰RNA分子(SiRNA)及其应用 | |
CN1809583A (zh) | 抑制hif-1表达的反义寡核苷酸 | |
CN1781930A (zh) | 含CpG单链脱氧核苷酸作为乙型肝炎病毒疫苗的佐剂 | |
CN1276094C (zh) | 用于诊断地中海贫血的dna芯片 | |
CN1827640A (zh) | 血管生成抑制多肽及其制备方法和应用 | |
CN1976946A (zh) | 诱导抗hcv有效ctl应答的超型表位、其编码寡核苷酸及其应用 | |
CN1268392C (zh) | 预防和治疗人丙型肝炎病毒感染的重组蛋白疫苗及其用途 | |
CN1954882A (zh) | 长效人重组可溶性肿瘤坏死因子α受体在制备防治肝衰竭药物中的用途 | |
CN1491719A (zh) | 蝉花在制备治疗慢性肾功能衰竭的药物中的应用 | |
CN1665835A (zh) | 草花粉过敏原Phl p4 的 DNA 序列和用重组方法进行的制备 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Cheng Jinshan Document name: Approval notice for cost mitigation |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: High tech Zone of Jilin province Changchun Chaoqun street 130103 No. 191 incubator building block A room 306 Patentee after: CHANGCHUN HUAPU BIOTECHNOLOGY CO.,LTD. Address before: 130061 Jilin, Changchun, No. 11 Xi'an Road, the United States building, room 1302 Patentee before: Changchun Huapu Biotechnology Co.,Ltd. |
|
CP03 | Change of name, title or address |
Address after: Room 1208-1210, block B, Zhongdan Ecological Life Science Industrial Park, no.3-1, xinjinhu Road, high tech Industrial Development Zone, Nanjing City, Jiangsu Province, 210061 Patentee after: Nanjing Huapu Biotechnology Co.,Ltd. Address before: 130103 Room 306, Block A, Incubation Building, 191 Chaoqun Street, Changchun High-tech Zone, Jilin Province Patentee before: CHANGCHUN HUAPU BIOTECHNOLOGY Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 214142 Room 301, No. 35-501, Changjiang South Road, Xinwu District, Wuxi City, Jiangsu Province Patentee after: Huapu Biotechnology (Jiangsu) Co.,Ltd. Address before: Room 1208-1210, block B, Zhongdan Ecological Life Science Industrial Park, no.3-1, xinjinhu Road, high tech Industrial Development Zone, Nanjing City, Jiangsu Province, 210061 Patentee before: Nanjing Huapu Biotechnology Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 051430 7-9/F, Building A2, No. 769, Taihang South Street, Shijiazhuang Hi tech Industrial Development Zone, Hebei Province Patentee after: Huapu Biotechnology (Hebei) Co.,Ltd. Address before: 214142 Room 301, No. 35-501, Changjiang South Road, Xinwu District, Wuxi City, Jiangsu Province Patentee before: Huapu Biotechnology (Jiangsu) Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CX01 | Expiry of patent term |
Granted publication date: 20090513 |
|
CX01 | Expiry of patent term |